Cellectis SA - Company Profile
Powered by 
All the sales intelligence you need on Cellectis SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cellectis SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cellectis SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cellectis SA (Cellectis) is a clinical-stage biopharmaceutical company that focuses on harnessing the immune system to target and eradicate cancer cells. Its activities carry out gene editing and the development of immunotherapy product candidates. Cellectis' pipeline products include UCART22 is for the treatment of acute lymphoblastic leukemia; UCART123 targets acute myeloid leukemia; UCART20x22 treats non hodgkin lymphoma; cemacabtagene ansegedleucel for large b cell lymphoma, chronic lymphocytic leukemia; ALLO-715, ALLO-605 are for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma. The company operates in France, the US, and the UK. Cellectis is headquartered in Paris, France.
Headquarters
France
Address
8, Rue De La Croix Jarry, Paris, Ile-de-France, 75013
Website
www.cellectis.com
Telephone
33 1 81691600
No of Employees
229
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALCLS (EPA)
Revenue (2024)
$79.6M
61.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-83.9%
(2024 vs 2023)
Market Cap*
$209.6M
Net Profit Margin (2024)
XYZ
-13.7%
(2024 vs 2023)
* As of and is in US$
Cellectis SA premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| UCART22: Acute Lymphoblastic Leukemia |
| UCART123: Acute Myeloid Leukemia |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Cellectis SA | Genfit SA | Median Technologies SA | Biocure Technology Inc | Cellectis Biologics Inc |
|---|---|---|---|---|---|
| Headquarters | France | France | France | Canada | United States of America |
| City | Paris | Loos | Valbonne | Vancouver | - |
| State/Province | Ile-de-France | Bretagne | Ile-de-France | British Columbia | - |
| No. of Employees | 229 | 180 | 164 | - | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andre Choulika, Ph.D. | Director; Chief Executive Officer | Executive Board | - | - |
| Adrian Kilcoyne, MD | Chief Medical Officer | Senior Management | - | - |
| Stephan Reynier | Chief Regulatory and Pharmaceutical Compliance Officer | Senior Management | 2011 | 55 |
| David Sourdive, Ph.D. | Co Founder; Executive Vice President - CMC and Manufacturing | Senior Management | - | - |
| Steve Doares, Ph.D. | Senior Vice President - US Manufacturing; Head - Site | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer